Drug Discovery Industry Research

Find market research and analysis on drug discovery. Our industry research reports give you a comprehensive look into market conditions and forecasts, in addition to product trends and analyses. Industry overviews, market share and growth, sales statistics and projections, and company profiles are also featured.

	Title	Published	Price
1	Prostate Cancer Drug Discoveries: What the Future Holds	Nov 2009	$2,460.00
	Prostate cancer is the second leading cause of cancer in the US and the third most common cancer worldwide. More than two million men in the US suffer with prostate cancer. Find out more about more... Published by: Espicom Healthcare Intelligence | Search inside this report
2	Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)	Nov 2009	$223.00
	The Competitive Intelligence Report Thrombopoiesis Stimulating Agents (TPO, IL-11) as of November 2009 provides information on thrombopoiesis stimulating agents targeting the thrombopoietin, interleukin-11 or other receptors on the market and in development. The product portfolio more... Published by: La Merie S.L. | Search inside this report
3	Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)	Nov 2009	$297.00
	The Competitive Intelligence Report FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART) as of November 2009 provides a competitor analysis in the development pipeline of novel recombinant, transgenic and oral FSH, hCG more... Published by: La Merie S.L. | Search inside this report
4	Competitor Analysis: FGF-R Agonists and Antagonists	Nov 2009	$445.00
	The present Competitive Intelligence Report about FGF-R agonists and antagonists provides a competitor evaluation in the field of fibroblast growth factor receptor (FGF-R) or PDGF targeting molecules for wound healing, cardiac tissue repair, bone formation more... Published by: La Merie S.L.
5	BI for Drug Development: Oracle Introduces Clinical Development Analytics	Nov 2009	$1,500.00
	This IDC Health Insights Perspective highlights the announcement of a dedicated life science business intelligence (BI) solution introduced recently at Oracle OpenWorld 2009 that promises to deliver actionable insights into clinical development processes. Oracle Clinical more... Published by: IDC | Search inside this report
6	Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis	Nov 2009	$175.00
	Pharmaceutical is one of the most intense “Knowledge Driven” industries, which is continually in a state of dynamic transition.Diversities in life forms and diseases pose stiff challenge to the design of specific and targeted solutions. more... Published by: Aruvian's R'search | Search inside this report
7	Competitor Analysis: TGF-R Agonists and Antagonists	Nov 2009	$297.00
	The present Competitive Intelligence Report about TGF-R agonists and antagonists provides a competitor evaluation in the field of transforming growth factor receptor (TGF-R) or TGF targeting molecules for tissue healing or treatment of cancer and more... Published by: La Merie S.L.
8	Protein Kinase Therapeutics in Oncology - Where to Commercialize?	Oct 2009	$3,500.00
	This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of more... Published by: BioSeeker Group AB
9	CDK Inhibitors Patent Landscape 2009	Oct 2009	$1,645.00
	IP Overview presents a patent landscape analysis of the CDK Inhibitor field. Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative dis orders such as Alzheimer’s disease and proliferative more... Published by: France Innovation Scientifique et Transfer | Search inside this report
10	Antidiabetics in Australia Market Forecast	Oct 2009	$5,700.00
	Introduction Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest more... Published by: Datamonitor
11	Plunkett's Health Care Technologies Overview 2010 (Summary)	Oct 2009	$199.99
	This summary contains the complete technologies section excerpted from the highly-acclaimed Plunkett's Health Care Industry Almanac. This report will be your ready-reference guide to new and developing health care technologies. Technology topics range from stem more... Published by: Plunkett Research, Ltd. | Search inside this report
12	Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases	Oct 2009	$2,250.00
	Introduction Biomarkers and imaging tools are enabling technologies in today’s clinical research efforts for neurological diseases. Whether to improve upon existing methods for monitoring disease progression or to discover validated measures to detect diseases earlier more... Published by: Decision Resources
14	Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market	Oct 2009	$11,400.00
	Introduction Drugs with new mechanisms, in particular Pfizer’s oral JAK inhibitor CP-690,550 and Chugai/Roche’s Actemra (tocilizumab), will launch for rheumatoid arthritis and should offer advantages over current therapies, but do not come without some safety signals. more... Published by: Datamonitor
15	Commercial Insight: Antidepressants - Novel mechanism offers hope in depressed market	Oct 2009	$15,200.00
	Introduction With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to decline at a compound annual growth rate of -2.0% (20082018). However, an antidepressant with a novel mechanism of action has huge commercial more... Published by: Datamonitor
16	Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth	Oct 2009	$15,200.00
	Introduction The Parkinson's disease market is approaching maturity, with the threat of generic incursion evident in each drug class. Although growth will be stifled by generic launches, relatively successful lifecycle management strategies and new product launches more... Published by: Datamonitor
17	Orphan Drug Strategies	Oct 2009	$3,800.00
	Introduction With the pharmaceutical industry reducing its focus on the primary care blockbuster model, Big Pharma is now looking towards the development and commercialization of more niche, high value, often biologic therapies, for the treatment of more... Published by: Datamonitor
18	Parkinson's Disease Market Forecast	Oct 2009	$15,200.00
	Introduction The Parkinson's disease market is approaching maturity, with the threat of generic incursion evident in each drug class. Although growth will be stifled by generic launches, relatively successful lifecycle management strategies and new product launches more... Published by: Datamonitor
19	Pipeline Insight: HIV - The Age of Convenience	Oct 2009	$11,400.00
	Introduction Three new partnerships are reshaping the competitive environment in HIV. Most notably, Tibotec/Johnson & Johnson is linking up with Gilead to combine their Phase III drug rilpivirine with Truvada to create a new gold standard more... Published by: Datamonitor
20	The World Market for Addiction Disorders, 2009 - 2016	Oct 2009	$2,345.00
	The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer's recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development more... Published by: Spectra Intelligence | Search inside this report
21	Competitor Analysis: Coagulation Factors	Oct 2009	$2,115.00
	The present Competitive Intelligence Report about Coagulation Factors provides a competitor evaluation in the field of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of more... Published by: La Merie S.L.
22	Competitor Analysis: PDGF-R Agonists and Antagonists	Oct 2009	$1,269.00
	The present Competitive Intelligence Report about PDGF-R agonists and antagonists provides a competitor evaluation in the field of platelet derived growth factor receptor (PDGF-R) or PDGF targeting molecules for wound healing, bone formation or treatment more... Published by: La Merie S.L.
23	Infectious Diseases Drugs Markets	Oct 2009	$3,400.00
	According to the World Health Organization (WHO), six infectious diseases--pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS--account for half of all premature deaths worldwide, killing mostly children and young adults. What’s more, threatening pandemics such more... Published by: Trimark Publications
24	The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)	Oct 2009	$3,500.00
	The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness more... Published by: Kalorama Information
25	Contract Pharmaceutical Manufacturing, Research and Packaging	Oct 2009	$4,850.00
	REPORT HIGHLIGHTS Overall sales in the pharmaceutical contract manufacturing and contract research market were worth nearly $143 million in 2007, which increased to an estimated $177 million in 2009. By 2014, sales are more... Published by: BCC Research | Search inside this report
	Title	Published	Price